PDF(Pubmed)
Abstract：
Fungal infections usually occur in immunocompromised patients. Intravenous immunoglobulin (IVIG) has been used as therapeutic interventions for many infectious diseases, but seldom applied in mycosis due to unknown antifungal specificity. This study aims to determine the presence of antifungal antibodies in IVIG. Binding reactivity of IVIG with crude and recombinant antigens of Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans and Talaromyces marneffei were observed in a dose-dependent manner, similar with mixed normal human sera. The antifungal specificity was further confirmed by competitive enzyme-linked immunosorbent assays (ELISA) inhibited by rabbit specific antifungal polyclonal antibodies (PAbs) and homogenous crude antigens with inhibitions of 65.5-87.2% and 73.1-94.2%, respectively. Moreover, IVIG also reacted with fungal glycoproteins (Csa2, Cpl1 and Mp1p) in a dose-dependent way, which was inhibited by specific rabbit PAbs and homogenous antigens with different inhibitions and pulled down 72.8-83.8% of specific antibodies if preabsorption IVIG with Dynabeads® coupled with homogenous glycoproteins. These results furthermore verified the antifungal specificity of IVIG. Among four brands of IVIG, there was different antifungal IgG against C. albicans (P < 0.05) and C. neoformans (P < 0.05), while no difference for A. fumigatus (P = 0.086) and T. marneffei (P = 0.057). IVIG contained a significantly higher level of specific IgG for C. albicans than other three fungi (P <0.001). In conclusion, we proved antifungal IgG against C. albicans, A. fumigatus, C. neoformans and T. marneffei present in IVIG, which might be expected to provide a possible immunoregulation choice for mycosis and an evaluation to humoral immunity against fungi.
摘要：
真菌感染通常发生在免疫功能低下的患者中。静脉免疫球蛋白（IVIG）已被用作许多传染病的治疗干预措施，但由于未知的抗真菌特异性，很少用于真菌病。本研究旨在确定IVIG中抗真菌抗体的存在。IVIG与白色念珠菌的粗抗原和重组抗原的结合反应性，烟曲霉,以剂量依赖性方式观察到新生隐球菌和马尔尼菲Talaromyces，与正常人混合血清相似。通过兔特异性抗真菌多克隆抗体（PAb）和均质粗抗原抑制的竞争性酶联免疫吸附测定（ELISA）进一步证实了抗真菌特异性，抑制率为65.5-87.2％和73.1-94.2％，分别。此外，IVIG还以剂量依赖的方式与真菌糖蛋白（Csa2，Cpl1和Mp1p）反应，如果预吸收IVIG与Dynabeads®偶联同源糖蛋白，则其被特异性兔PAb和具有不同抑制作用的同源抗原抑制，并降低72.8-83.8％的特异性抗体。这些结果进一步证实了IVIG的抗真菌特异性。在IVIG的四个品牌中，抗真菌IgG对白色念珠菌(P<0.05)和新型念珠菌(P<0.05),而烟曲霉(P=0.086)和马尼菲(P=0.057)没有差异。与其它三种真菌相比,IVIG含有显著更高水平的白色念珠菌特异性IgG(P<0.001)。总之,我们证明了抗白色念珠菌的抗真菌IgG,A.烟,出现在IVIG中的C.新生动物和T.marneffei，这可能有望为真菌病提供可能的免疫调节选择，并评估针对真菌的体液免疫。
